Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2010, Article ID 610479, 7 pages
http://dx.doi.org/10.1155/2010/610479
Review Article

Macrophage Migration Inhibitory Factor: Critical Role in Obesity, Insulin Resistance, and Associated Comorbidities

1Department of Biosciences, Gaubius Laboratory, TNO-Quality of Life, Zernikedreef 9, 2301 CE Leiden, The Netherlands
2Department of Medicine and Pathology, School of Medicine, Yale University, New Haven, CT 06510, USA

Received 23 November 2009; Accepted 7 January 2010

Academic Editor: Oreste Gualillo

Copyright © 2010 Robert Kleemann and Richard Bucala. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Kelly, W. Yang, C.-S. Chen, K. Reynolds, and J. He, “Global burden of obesity in 2005 and projections to 2030,” International Journal of Obesity, vol. 32, no. 9, pp. 1431–1437, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. P. S. Yusuf, S. Hawken, S. Ounpuu et al., “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study,” The Lancet, vol. 364, no. 9438, pp. 937–952, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J.-P. Despres, I. Lemieux, J. Bergeron et al., “Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 6, pp. 1039–1049, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Xu, G. T. Barnes, Q. Yang et al., “Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1821–1830, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-P. Després, “Is visceral obesity the cause of the metabolic syndrome?” Annals of Medicine, vol. 38, no. 1, pp. 52–63, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Zernecke, J. Bernhagen, and C. Weber, “Macrophage migration inhibitory factor in cardiovascular disease,” Circulation, vol. 117, no. 12, pp. 1594–1602, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Y. Lan, “Role of macrophage migration inhibition factor in kidney disease,” Nephron—Experimental Nephrology, vol. 109, no. 3, pp. e79–e83, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Flaster, J. Bernhagen, T. Calandra, and R. Bucala, “The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity,” Molecular Endocrinology, vol. 21, no. 6, pp. 1267–1280, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Lue, R. Kleemann, T. Calandra, T. Roger, and J. Bernhagen, “Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease,” Microbes and Infection, vol. 4, no. 4, pp. 449–460, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Dandona, A. Aljada, H. Ghanim et al., “Increased plasma concentration of macrophage Migration Inhibitory Factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 10, pp. 5043–5047, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Ghanim, A. Aljada, D. Hofmeyer, T. Syed, P. Mohanty, and P. Dandona, “Circulating mononuclear cells in the obese are in a proinflammatory state,” Circulation, vol. 110, no. 12, pp. 1564–1571, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Sumarac-Dumanovic, D. Stevanovic, A. Ljubic et al., “Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women,” International Journal of Obesity, vol. 33, no. 1, pp. 151–156, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. T. S. Church, M. S. Willis, E. L. Priest et al., “Obesity, macrophage migration inhibitory factor, and weight loss,” International Journal of Obesity, vol. 29, no. 6, pp. 675–681, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. W. H.-H. Sheu, T.-M. Chang, W.-J. Lee et al., “Effect of weight loss on proinflammatory state of mononuclear cells in obese women,” Obesity, vol. 16, no. 5, pp. 1033–1038, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. F. M. H. Van Dielen, W. A. Buurman, M. Hadfoune, J. Nijhuis, and J. W. Greve, “Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 8, pp. 4062–4068, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Herder, N. Klopp, J. Baumert et al., “Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984–2002,” Diabetologia, vol. 51, no. 2, pp. 276–284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Petrovsky, L. Socha, D. Silva, A. B. Grossman, C. Metz, and R. Bucala, “Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator,” Immunology and Cell Biology, vol. 81, no. 2, pp. 137–143, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Sakaue, S. Ishimaru, N. Hizawa et al., “Promoter polymorphism in the macrophage migration inhibitory factor gene is associated with obesity,” International Journal of Obesity, vol. 30, no. 2, pp. 238–242, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. J. A. Baugh, S. Chitnis, S. C. Donnelly et al., “A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis,” Genes and Immunity, vol. 3, no. 3, pp. 170–176, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. X. B. Zhong, L. Leng, A. Beitin et al., “Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-film biosensor chips and application to rural field studies,” Nucleic Acids Research, vol. 33, no. 13, article e121, 2005. View at Google Scholar · View at Scopus
  21. T. R. D. J. Radstake, F. C. G. J. Sweep, P. Welsing et al., “Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor,” Arthritis and Rheumatism, vol. 52, no. 10, pp. 3020–3029, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Skurk, C. Herder, I. Kraft, S. Muller-Scholze, H. Hauner, and H. Kolb, “Production and release of macrophage migration inhibitory factor from human adipocytes,” Endocrinology, vol. 146, no. 3, pp. 1006–1011, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Koska, N. Stefan, S. Dubois et al., “mRNA concentrations of MIF in subcutaneous abdominal adipose cells are associated with adipocyte size and insulin action,” International Journal of Obesity, vol. 33, no. 8, pp. 842–850, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Yabunaka, J. Nishihira, Y. Mizue et al., “Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes,” Diabetes Care, vol. 23, no. 2, pp. 256–258, 2000. View at Google Scholar · View at Scopus
  25. B. Vozarova, N. Stefan, R. Hanson et al., “Plasma concentrations of macrophage migration inhibitory factor are elevated in Pima Indians compared to Caucasians and are associated with insulin resistance,” Diabetologia, vol. 45, no. 12, pp. 1739–1741, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Herder, H. Kolb, W. Koenig et al., “Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4),” Diabetes Care, vol. 29, no. 2, pp. 368–371, 2006. View at Google Scholar · View at Scopus
  27. C. Herder, M. Peltonen, W. Koenig et al., “Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study,” Diabetes, vol. 55, no. 8, pp. 2340–2346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. M. D. Sanchez-Nino, A. B. Sanz, P. Ihalmo et al., “The MIF receptor CD74 in diabetic podocyte injury,” Journal of the American Society of Nephrology, vol. 20, no. 2, pp. 353–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Mitamura, S. Takeuchi, A. Matsuda, Y. Tagawa, Y. Mizue, and J. Nishihira, “Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy,” British Journal of Ophthalmology, vol. 84, no. 6, pp. 636–639, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Tashimo, Y. Mitamura, S. Nagai et al., “Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy,” Diabetic Medicine, vol. 21, no. 12, pp. 1292–1297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Weigelt, B. Rose, U. Poschen et al., “Immune mediators in patients with acute diabetic foot syndrome,” Diabetes Care, vol. 32, no. 8, pp. 1491–1496, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. D. D. Sears, G. Hsiao, A. Hsiao et al., “Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 44, pp. 18745–18750, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Bojunga, K. Kusterer, M. Bacher, R. Kurek, K.-H. Usadel, and H. Renneberg, “Macrophage migration inhibitory factor and development of type-1 diabetes in non-obese diabetic mice,” Cytokine, vol. 21, no. 4, pp. 179–186, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Cvetkovic, Y. Al-Abed, D. Miljkovic et al., “Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes,” Endocrinology, vol. 146, no. 7, pp. 2942–2951, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Stosic-Grujicic, I. Stojanovic, D. Maksimovic-Ivanic et al., “Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus,” Journal of Cellular Physiology, vol. 215, no. 3, pp. 665–675, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Waeber, T. Calandra, R. Roduit et al., “Insulin secretion is regulated by the glucose-dependent production of islet ß cell macrophage migration inhibitory factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4782–4787, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Benigni, T. Atsumi, T. Calandra et al., “The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle,” Journal of Clinical Investigation, vol. 106, no. 10, pp. 1291–1300, 2000. View at Google Scholar · View at Scopus
  38. T. Atsumi, Y.-R. Cho, L. Leng et al., “The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation,” Journal of Immunology, vol. 179, no. 8, pp. 5399–5406, 2007. View at Google Scholar · View at Scopus
  39. J. Hirokawa, S. Sakaue, S. Tagami et al., “Identification of macrophage migration inhibitory factor in adipose tissue and its induction by tumor necrosis factor-a,” Biochemical and Biophysical Research Communications, vol. 235, no. 1, pp. 94–98, 1997. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Sakaue, J. Nishihira, J. Hirokawa et al., “Regulation of macrophage migration inhibitory factor (MIF) expression by glucose and insulin in adipocytes in vitro,” Molecular Medicine, vol. 5, no. 6, pp. 361–371, 1999. View at Google Scholar · View at Scopus
  41. E. J. Miller, J. Li, L. Leng et al., “Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart,” Nature, vol. 451, no. 7178, pp. 578–582, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Verschuren, T. Kooistra, J. Bernhagen et al., “MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease,” Circulation Research, vol. 105, no. 1, pp. 99–107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. J. G. Neels and J. M. Olefsky, “Inflamed fat: what starts the fire?” Journal of Clinical Investigation, vol. 116, no. 1, pp. 33–35, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Carlsen, F. Haugen, S. Zadelaar et al., “Diet-induced obesity increases NF-?B signaling in reporter mice,” Genes and Nutrition, vol. 4, no. 3, pp. 215–222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. A. Amin, C. S. Haas, K. Zhu et al., “Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NF?B,” Blood, vol. 107, no. 6, pp. 2252–2261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Bernhagen, R. Krohn, H. Lue et al., “MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment,” Nature Medicine, vol. 13, no. 5, pp. 587–596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Verschuren, R. Kleemann, E. H. Offerman et al., “Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 1, pp. 161–167, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Fingerle-Rowson, D. R. Kaleswarapu, C. Schlander et al., “A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation,” Molecular and Cellular Biology, vol. 29, no. 7, pp. 1922–1932, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Kleemann, A. Kapurniotu, R. W. Frank et al., “Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase,” Journal of Molecular Biology, vol. 280, no. 1, pp. 85–102, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Kleemann, H. Rorsman, E. Rosengren, R. Mischke, N. T. Mai, and J. Bernhagen, “Dissection of the enzymatic and immunologic functions of macrophage migration inhibitory factor: full immunologic activity of N-terminally truncated mutants,” European Journal of Biochemistry, vol. 267, no. 24, pp. 7183–7192, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Kleemann, A. Kapurniotu, R. Mischke, J. Held, and J. Bernhagen, “Characterization of catalytic centre mutants of macrophage migration inhibitory factor (MIF) and comparison to Cys81Ser MIF,” European Journal of Biochemistry, vol. 261, no. 3, pp. 753–766, 1999. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Burger-Kentischer, H. Gobel, R. Kleemann et al., “Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF),” Atherosclerosis, vol. 184, no. 1, pp. 28–38, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. A. M. Carter, “Inflammation, thrombosis and acute coronary syndromes,” Diabetes and Vascular Disease Research, vol. 2, no. 3, pp. 113–121, 2005. View at Google Scholar · View at Scopus
  54. L. Verschuren, J. H. N. Lindeman, J. H. van Bockel, H. Abdul-Hussien, T. Kooistra, and R. Kleemann, “Up-regulation and coexpression of MIF and matrix metalloproteinases in human abdominal aortic aneurysms,” Antioxidants and Redox Signaling, vol. 7, no. 9-10, pp. 1195–1202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. J. H. N. Lindeman, H. Abdul-Hussien, A. F. M. Schaapherder et al., “Enhanced expression and activation of pro-inflammatory transcription factors distinguish aneurysmal from atherosclerotic aorta: IL-6- and IL-8-dominated inflammatory responses prevail in the human aneurysm,” Clinical Science, vol. 114, no. 11-12, pp. 687–697, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. J. H. N. Lindeman, H. Abdul-Hussien, J. H. van Bockel, R. Wolterbeek, and R. Kleemann, “Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm doxycycline selectively depletes aortic wall neutrophils and cytotoxic t cells,” Circulation, vol. 119, no. 16, pp. 2209–2216, 2009. View at Publisher · View at Google Scholar · View at Scopus